PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : P

Records returned : 208 (on 17 May 2024 at 10:56:38).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Paclitaxel
No Information Returned
Paclitaxel albumin
No Information Returned
Padimate O
No Information Returned
Palbociclib
No Information Returned
Palifermin
No Information Returned
Paliperidone
No Information Returned
Palivizumab
No Information Returned
Palonosetron hydrochloride
No Information Returned
04.06.00
Palonosetron with netupitant
Nausea and vomiting (chemotherapy induced)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD2
Pamidronate disodium
No Information Returned
Pancreatin
No Information Returned
Pancuronium bromide
No Information Returned
Panitumumab
No Information Returned
Panobinostat
No Information Returned
01.03.05
Pantoprazole
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
2nd line in adults without swallowing difficulties. (Suitable for patients that cannot have animal-derived products / capsules.)
Pantothenic acid (Calcium pantothenate)
No Information Returned
Papaveretum
No Information Returned
Papaverine hydrochloride
No Information Returned
04.07.01
Paracetamol
Pain
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
04.07.01
Paracetamol
Pyrexia
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Preferred
04.07.01
Paracetamol
Pyrexia
Green (see narrative)
Formulations :
  • Effervescent tablets
  • Soluble tablets
  • Suppositories
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Reserve for patients who cannot swallow solid dose forms. Soluble / effervescent preparations have a high sodium content and more expensive than ordinary tablets.
04.07.01
Paracetamol
Pyrexia
Green (see narrative)
Formulations :
  • Oral suspension
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
120mg/5ml and 250mg/5ml reserved for patients who cannot swallow solid dose forms. Non-formulary: Paracetamol oral suspension 500mg/5ml. Much more expensive. Use a soluble formulation.
04.07.01
Paracetamol
Pain
Green (see narrative)
Formulations :
  • Effervescent tablets
  • Soluble tablets
  • Suppositories
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Reserve for patients who cannot swallow solid dose forms. Soluble / effervescent preparations have a high sodium content and more expensive than ordinary tablets. Suppositories for use when oral route is not suitable
04.07.01
Paracetamol
Pain
Green (see narrative)
Formulations :
  • Oral suspension
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
120mg/5ml and 250mg/5ml reserved for patients who cannot swallow solid dose forms. Non-formulary: Paracetamol oral suspension 500mg/5ml. Much more expensive. Use a soluble formulation.
04.07.01
Paracetamol
Pain
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Prescribe in milligrams for doses <1g. Review infusion prescriptions after 48-72 hours. Note risk of overdose with IV paracetamol.
04.07.01
Paracetamol
Pyrexia
Red
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Important
Prescribe in milligrams for doses <1g Review infusion prescriptions after 48-72 hours. Note risk of overdose with IV paracetamol.
Paracetamol and caffeine
No Information Returned
Paracetamol and ibuprofen
No Information Returned
Paracetamol and phenylephrine hydrochloride
No Information Returned
Paracetamol combined preparations
No Information Returned
Paraffin hard
No Information Returned
Paraffin soft white
No Information Returned
Paraffin soft yellow
No Information Returned
11.08.01
Paraffin with lubricant
Dry eyes
Green
Formulations :
  • Eye ointment
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Moderate dry eye. Prescribe by brand: 1st line = HydraMed Night 2nd line = Moistueyes, Xailin Night, Hylo Night
Paraldehyde
No Information Returned
Parathyroid hormone
No Information Returned
Parecoxib sodium
No Information Returned
Paricalcitol
No Information Returned
Paritaprevir/ritonavir/ombitasvir
No Information Returned
Paromomycin sulfate
No Information Returned
Paroxetine hydrochloride
No Information Returned
Pasireotide
No Information Returned
Patiromer calcium
No Information Returned
Pazopanib
No Information Returned
Pegaptanib sodium
No Information Returned
Pegaspargase
No Information Returned
Pegfilgrastim
No Information Returned
Peginterferon alpha
No Information Returned
Peginterferon beta
No Information Returned
08.02.04
Peginterferon beta-1a
Multiple sclerosis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
BlueTeq
Pegvisomant
No Information Returned
Pembrolizumab
No Information Returned
Pemetrexed
No Information Returned
Penciclovir
No Information Returned
10.01.03
Penicillamine
Rheumatoid arthritis
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Severe disease only
Pentamidine isetionate
No Information Returned
Pentazocine hydrochloride
No Information Returned
Pentazocine lactate
No Information Returned
02.08.02
07.04.03
Pentosan polysulfate sodium
Glycosaminoglycan layer therapy (GAG therapy)
Red
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
R
NICE
Important
Urology consultants only
Pentostatin
No Information Returned
Pentoxifylline
No Information Returned
01.02.00
Peppermint oil
Muscle spasm
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
The gastro-resistant capsules (Mintec®) are the most cost-effective option for Primary Care. The modified-release capsules (Colpermin) contain arachis oil - not be taken by patients with a known peanut allergy
04.08.01
Perampanel
Epilepsy
Amber
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
04.09.01
Pergolide mesilate
Parkinson's disease
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
Pericyazine
No Information Returned
Perindopril arginine
No Information Returned
Perindopril arginine with diuretic
No Information Returned
Perindopril erbumine
No Information Returned
Perindopril erbumine with diuretic
No Information Returned
Perindopril tosilate
No Information Returned
Perindopril tosilate/indapamide
No Information Returned
Perindopril with calcium channel blocker
No Information Returned
Permethrin
No Information Returned
Perphenazine
No Information Returned
Pertuzumab
No Information Returned
04.07.02
Pethidine hydrochloride
Pain
Red
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Important
Acute pain, including obstetric analgesia
Phased formulations of ethinylestradiol
No Information Returned
Phenazone/lidocaine
No Information Returned
Phenelzine sulfate
No Information Returned
Phenindione
No Information Returned
04.08.01
04.08.02
Phenobarbital
Epilepsy
Blue
Formulations :
  • Elixir
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Important
Ensure that the patient is maintained on a specific manufacturer’s product
04.08.01
04.08.02
Phenobarbital
Epilepsy
Blue
Formulations :
  • Liquid
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Un
Important
Ensure that the patient is maintained on a specific manufacturer’s product
Unlicensed phenobarbital liquid 50mg/5ml (sugar and alcohol free) for paediatric use (as recommended by the RCPCH and NPPG).
04.08.01
04.08.02
Phenobarbital
Status epilepticus
Red
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Phenobarbital sodium
No Information Returned
Phenol
No Information Returned
Phenolphthalein and rhubarb
No Information Returned
Phenothrin
No Information Returned
Phenoxybenzamine hydrochloride
No Information Returned
Phenoxyethanol
No Information Returned
Phenoxymethylpenicillin (Penicillin V)
No Information Returned
Phenprocoumon
No Information Returned
Phentolamine mesilate
No Information Returned
Phentolamine/aviptadil
No Information Returned
Phenylbutazone
No Information Returned
Phenylephrine hydrochloride
No Information Returned
Phenylephrine hydrochloride and tropicamide
No Information Returned
Phenylprop hydrochloride/chlorphenamine maleate
No Information Returned
Phenylpropanolamine hydrochloride
No Information Returned
04.08.01
04.08.02
Phenytoin
Epilepsy
Blue
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
SA
Important
Ensure that the patient is maintained on a specific manufacturer’s product. Phenytoin sodium is NOT EQUIVALENT to Phenytoin base (suspension). When switching between products, 100mg of phenytoin sodium is approximately equivalent to 92mg of phenytoin base.
04.08.01
04.08.02
Phenytoin
Status epilepticus
Red
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Phenytoin sodium
No Information Returned
Pholcodine
No Information Returned
Phosphates
No Information Returned
Phosphates (Rectal)
No Information Returned
Phytomenadione
No Information Returned
Pilocarpine hydrochloride
No Information Returned
Pilocarpine nitrate
No Information Returned
Pimecrolimus
No Information Returned
Pimozide
No Information Returned
Pindolol
No Information Returned
Pindolol with diuretic
No Information Returned
Pioglitazone hydrochloride
No Information Returned
Piperacillin sodium/tazobactam sodium
No Information Returned
Piperaquine phosphate/artenimol
No Information Returned
Piperazine
No Information Returned
Pipobroman
No Information Returned
Pipotiazine palmitate
No Information Returned
04.08.01
04.09.03
Piracetam
Epilepsy
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Pirenzepine
No Information Returned
03.11.01
Pirfenidone
Idiopathic pulmonary fibrosis
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
NHSE Specialist Centre only
10.01.01
10.03.02
Piroxicam
Osteoarthritis
Green
Formulations :
  • Gel
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
0.5% gel. Low cost option for primary care.
04.04.00
Pitolisant hydrochloride
Narcolepsy
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Pivmecillinam hydrochloride
No Information Returned
04.07.04
Pizotifen
Migraine (prevention)
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Review existing patients and consider alternative. Discontinuation of pizotifen requires gradual withdrawal.
Pizotifen malate
No Information Returned
Plerixafor
No Information Returned
Pneumococcal
No Information Returned
Podophyllotoxin
No Information Returned
Podophyllum resin
No Information Returned
Policosanol
No Information Returned
Polihexanide
No Information Returned
Poliomyelitis
No Information Returned
Pollen allergy preparations
No Information Returned
Polymyxin B sulphate
No Information Returned
Polymyxins
No Information Returned
Polynoxylin
No Information Returned
Polysaccharide-iron complex
No Information Returned
Polythiazide
No Information Returned
Polyvinyl alcohol
No Information Returned
Pomalidomide
No Information Returned
Ponatinib
No Information Returned
Porfimer sodium
No Information Returned
Posaconazole
No Information Returned
Potassium bicarbonate
No Information Returned
Potassium bromide
No Information Returned
Potassium chloride
No Information Returned
07.04.03
Potassium citrate
Alkalinisation of urine
Green
Formulations :
  • Effervescent tablets
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Can be purchased from a pharmacy
Potassium hydroxyquinoline sulphate
No Information Returned
Potassium iodate
No Information Returned
Potassium iodide
No Information Returned
Potassium permanganate
No Information Returned
07.02.02
Povidone iodine
Bacterial vaginosis
Non Formulary
Formulations :
  • Pessaries
  • Vaginal gel
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Povidone K 25
No Information Returned
Povidone-iodine
No Information Returned
Powder 1 - 2.2 kcal/ml soup (0913011)
No Information Returned
Powder 1.5 kcal/ml smoothie (0913011)
No Information Returned
Powder 1.6 kcal/ml milkshake (0913011)
No Information Returned
Powder 2 kcal/ml m/sk higher volume, higher energy (0913011)
No Information Returned
Powder 2.3 - 2.4 kcal/ml milkshake lower volume (0913011)
No Information Returned
Powdered opium
No Information Returned
04.09.01
Pramipexole
Restless Leg Syndrome
Green
Formulations :
  • Immediate release tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
Patients with severe symptoms, who are obese, co-morbid depression, increased risk of falls or cognitive impairment
04.09.01
Pramipexole
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Pramipexole
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Pramipexole
Parkinson's disease (neuroprotective therapy)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Prasterone
No Information Returned
Prasugrel
No Information Returned
Pravastatin sodium
No Information Returned
Praziquantel
No Information Returned
02.05.04
07.04.01
Prazosin hydrochloride
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
01.05.02
06.03.02
Prednisolone
Inflammatory bowel disease
Non Formulary
Formulations :
  • Foam enema
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
Budesonide rectal foam is preferred. Steroid safety considerations
Prednisolone acetate
No Information Returned
Prednisolone sodium metasulphobenzoate
No Information Returned
Prednisolone sodium phosphate
No Information Returned
Prednisone
No Information Returned
04.07.03
04.07.04
04.08.01
Pregabalin
Restless Leg Syndrome
Green
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Preferred
Patients with severe sleep disturbance, RLS-related / co-morbid pain or history of impulse control disorder
04.07.03
04.07.04
04.08.01
Pregabalin
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
04.07.03
04.07.04
04.08.01
Pregabalin
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
SA
Important
Gabapentin is preferred due to lower potential for misuse. Pregabalin capsules more cost effective than tablets
04.07.03
04.07.04
04.08.01
Pregabalin
Epilepsy
Blue
Formulations :
  • Capsules
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Important
Capsules are more cost effective than tablets
04.07.03
04.07.04
04.08.01
Pregabalin
Pain (non-malignant)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
04.07.03
04.07.04
04.08.01
Pregabalin
Migraine (prevention)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Preparations for other vaginal infections
No Information Returned
Pridinol
No Information Returned
Pridinol mesilate
No Information Returned
Prilocaine hydrochloride
No Information Returned
Primaquine
No Information Returned
04.08.01
04.09.03
Primidone
Epilepsy
Blue
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe by brand - ensure patient is maintained on a specific product.
04.08.01
04.09.03
Primidone
Essential tremor
Blue
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Initiation by specialist before transfer to Primary Care
Pristinamycin
No Information Returned
10.01.04
Probenecid
Hyperuricaemia and Gout
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
U
Important
Named-patient supply only
Procainamide hydrochloride
No Information Returned
Procaine hydrochloride
No Information Returned
Procarbazine hydrochloride
No Information Returned
04.06.00
Prochlorperazine maleate
Vestibular disorders
Green
Formulations :
  • Buccal tablets
  • Oral solution
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
04.06.00
Prochlorperazine maleate
Nausea and vomiting (pregnancy)
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
Preferred
1st line treatment option.
04.06.00
Prochlorperazine maleate
Nausea and vomiting (pregnancy)
Green (see narrative)
Formulations :
  • Buccal/sublingual
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
An option for patients with swallowing difficulties
Prochlorperazine mesilate
No Information Returned
04.09.02
Procyclidine hydrochloride
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Proflavine
No Information Returned
Proflavine hemisulphate
No Information Returned
Progesterone
No Information Returned
Proguanil hydrochloride
No Information Returned
Proguanil hydrochloride with atovaquone
No Information Returned
Promazine hydrochloride
No Information Returned
03.04.01
04.06.00
Promethazine hydrochloride
Vestibular disorders
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
03.04.01
04.06.00
Promethazine hydrochloride
Nausea and vomiting (pregnancy)
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
Preferred
1st line treatment option.
03.04.01
04.06.00
Promethazine hydrochloride
Nausea and vomiting (pregnancy)
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
An option for patients with swallowing difficulties
04.06.00
Promethazine teoclate
Nausea and vomiting (pregnancy)
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
Preferred
1st line treatment option. This is a lower cost promethazine option for primary care but note difference in CKS recommended dose.
Propafenone hydrochloride
No Information Returned
Propamidine isetionate
No Information Returned
Propantheline bromide
No Information Returned
07.04.02
Propiverine hydrochloride
Overactive bladder (adults)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Propofol
No Information Returned
02.04.00
04.07.04
Propranolol hydrochloride
Migraine (prevention)
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Propranolol hydrochloride with diuretic
No Information Returned
Propylthiouracil
No Information Returned
Protamine sulfate
No Information Returned
Protamine zinc insulin
No Information Returned
Protein C concentrate
No Information Returned
Protirelin
No Information Returned
Proxymetacaine hydrochloride
No Information Returned
Prucalopride
No Information Returned
Pseudoephedrine hydrochloride
No Information Returned
Pseudoephedrine hydrochloride combinations
No Information Returned
Pseudoephedrine hydrochloride/dextromethorphan hydrobromide
No Information Returned
Pseudoephedrine sulfate combinations
No Information Returned
Pyrazinamide
No Information Returned
10.02.01
Pyridostigmine bromide
Myasthenia gravis
Blue
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Pyridoxine hydrochloride
No Information Returned
Pyrimethamine
No Information Returned
Pyrimethamine with dapsone
No Information Returned
Pyrimethamine with sulfadoxine
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More